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Background: Diabetes is the most common risk factor for end-stage renal disease (ESRD) and has been associated
with increased risk of death. In order to better understand the influence of diabetes on outcomes in hemodialysis,
we examine the risk of death of diabetic participants in the HEMODIALYSIS (HEMO) study.
Methods: In the HEMO study, 823 (44.6%) participants were classified as diabetic. Using the Schoenfeld residual
test, we found that diabetes violated the proportional hazards assumption. Based on this result, we fit two
non-proportional hazard models: Cox’s time varying covariate model (Cox-TVC) that allows the hazard for diabetes
to change linearly with time and Gray’s time-varying coefficient model.
Results: Using the Cox-TVC, the hazard ratio (HR) for diabetes increased with each year of follow up (p = 0.02) for
all cause mortality. Using Gray’s model, the HR for diabetes ranged from 1.41 to 2.21 (p <0.01). The HR for diabetes
using Gray’s model exhibited a different pattern, being relatively stable at 1.5 for the first 3 years in the study and
increasing afterwards.
Conclusion: Risk of death associated with diabetes in ESRD increases over time and suggests that an increasing risk
of death among diabetes may be underappreciated when using conventional survival models.
Keywords: Cox regression, Diabetes, ESRD, Hemodialysis, Proportional hazard, Survival model, Time varying
coefficient model, Time dependent covariate.Background
Diabetes is one of the leading causes of end stage renal
disease in the U.S. [1] and ESRD due to type 2 diabetes
mellitus has been increasing worldwide [2,3]. Diabetes
has known macrovascular complications such as myo-
cardial infarction and stroke. In addition, diabetes affects
the microvascular circulation, impairs neutrophil func-
tion which increases the risk of infections which may be
life threatening [4,5], and also leads to an accumulation
of advanced-glycosylation end products and oxidative
stress. Diabetic status has been associated with increased
cause of death in international dialysis cohorts [1,6]. In
the case of diabetes, effects of the disease may accumu-
late over time resulting in a hazard function that is in-
creasing at a greater rate over time than that in subjects
without diabetes. Since diabetes is such a prevalent and* Correspondence: markunruh@gmail.com
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reproduction in any medium, provided the orimportant comorbid condition in the ESRD population,
it is critical to better understand the longitudinal associ-
ation of diabetes with cause-specific and overall mortal-
ity. The relationship between diabetes and time-to-death
in ESRD populations is usually demonstrated using the
Cox proportional hazards (Cox-PH) model. Though the
Cox-PH model is a useful tool for assessing the relation-
ship of diabetes to time-to-event data, it requires that
the proportional hazards (PH) assumption be met; spe-
cifically that the hazard in the diabetic group is a con-
stant proportion of the hazard in the non-diabetic
group. Cox-PH model may not perform well when used
to study exposures that are cumulative over time [7].
There were a substantial number of diabetics studied
in the HEMO Study, a large multi-center trial of
hemodialysis patients which examined the effects on
hemodialysis patient survival of dose (eKt/V 1.45 vs.
1.05) and hemodialyzer flux (high vs. low). The HEMO
Study provided an opportunity to assess the extenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sattar et al. BMC Nephrology 2012, 13:130 Page 2 of 9
http://www.biomedcentral.com/1471-2369/13/130to which diabetes influences survival in prevalent
hemodialysis patients since the study has a prospective
follow-up, careful characterization of the severity of
comorbid conditions, rigorous classification of the cause
of death, and used diabetes as a stratification variable.
Since dialysis dose and membrane flux were interven-
tions in the HEMO Study, stratification by diabetes
ensures that these factors were accounted for when
assessing the relationship between diabetes and survival
outcomes. In this report, we take advantage of the de-
sign features of the randomized controlled clinical trial
to examine the risk of death for the diabetic participants
in the HEMO study and to compare different
approaches for estimation of the risk of death in dia-
betics with ESRD. To address the issue of non-
proportional hazards we applied models that allow for
non-proportionality of conditional hazards through the
introduction of spline-based models. Gray’s spline-based
extension of the Cox proportional hazards model allows
for modeling of the effects of covariates without making
the assumption of proportional hazards [8,9]. Specific-
ally, we examine the risk of all-cause and cause-specific
mortality of diabetic patients on hemodialysis over time
and compare the performance of the standard Cox
Model, a Cox model assuming a linear change in the
hazard with time (Cox-TVC) and Gray’s model in pro-
viding an estimate of risk of death in this patient
population.
Methods
Subjects
The HEMO Study was a fifteen-center randomized clin-
ical trial of the effects of hemodialysis dose and mem-
brane flux on mortality and morbidity in patients
undergoing chronic dialysis [1]. Patients in this study
were randomized to either standard or high dose (eKt/V
of 1.05 vs. 1.45, respectively) and to either high or low
flux membranes (beta-2 microglobulin clearance of
<10 ml/min or >20 ml/min, respectively). Enrollment in
the HEMO Study began in March 1995 and ended in
October 2000 with a total of 1846 patients enrolled in
the study. Patient eligibility criteria have been described
previously [6]. The primary endpoint was all-cause
mortality [10]. The Institutional Review Boards at the
15 institutions approved the study protocol and
written informed consent was obtained from all study
participants.
Data collection
Demographic information and clinical history were col-
lected through review of medical records and self-
reported questionnaires. The race of the respondent was
assessed by self-report and categorized as African-
American or non-African American include those self-identified as white, Asian, Native American or ‘other’.
Clinical data including laboratory measurements were
obtained using standardized protocols. Comorbidity was
assessed at baseline using the Index of Coexistent Dis-
ease (ICED) calculated without using the diabetes score
[6,11,12]. The ICED aggregates the presence and severity
of 19 medical conditions and 11 physical impairments
into 2 summary indices: the Index of Disease Severity
(IDS) and the Index of Physical Impairment (IPI) [12].
Diabetes was defined using the ICED classification as
present if the patient had been previously diagnosed
with diabetes, had been prescribed a diabetic diet, was
receiving insulin or oral hypoglycemic agents or had
been previously admitted to the hospital for hypergly-
cemia or ketoacidosis.
Classification of cause-specific mortality in HEMO
The duration of follow-up monitoring ranged from
0.003 to 6.639 yr, depending on the time of
randomization. The mean actual follow-up duration was
2.84 yr. The determination of cause-specific mortality in
the HEMO Study has been previously described [6,7,9].
Briefly, causes of deaths were independently reviewed by
two clinicians blinded to the intervention assignments.
The members assigned one primary and up to three sec-
ondary causes of death based on their clinical judgment
from the narrative description of the death, hospital dis-
charges, laboratories, and study data. When agreement
could not be reached, the case was adjudicated by the
full Outcome Review Committee. The cause-specific in-
fectious, cardiac, and cardiovascular deaths were
selected since these are the most common etiologies of
death among hemodialysis patients. The four cardiac
causes of death were: (1) Ischemic Heart Disease;
(2) congestive heart failure; (3) arrhythmias, and
(4) other heart diseases. The categorization of cardiovas-
cular deaths included cardiac, cerebrovascular and vas-
cular causes of death.
Covariates for all-cause and cause-specific mortality
In order to account for residual confounding on mortal-
ity we adjusted our survival analyses for the following
baseline patient characteristics that have been found to
be associated with the mortality of ESRD patients in pre-
vious studies. 1) Demographic: age, gender, race and
body mass index (BMI) 2) Dialysis Related Factors: Dur-
ation of ESRD (also known as “vintage”), residual renal
function (absent or present based on a residual urine
output of less than 200 ml/day) and dialysis access. Dia-
lysis access was defined as dialysis catheter vs. all other
(Arteriovenous Fistula (AVF), grafts or other) 3) Labora-
tory tests: calcium (mg/dL), phosphorus (mg/dL), serum
total cholesterol (mg/dl), and serum albumin (g/dl) 4)
Comorbidity: ICED score (computed without the
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lected in the setting of a randomized trial, we included
treatment assignment as covariates (dialysis dose and
membrane flux).Statistical analysis
In this secondary analysis of the HEMO study data,
baseline demographic, socioeconomic and laboratory
variables were summarized as mean(standard deviation)
for normally distributed continuous variables and as per-
centages for categorical variables. Skewed continuous
variables were summarized using the median ± inter-
quartile range. Differences in summary statistics were
tested, 1) for the normally distributed variables using a
two sided t-test 2) for skewed continuous variables using
a rank sum test, and 3) for categorical variables using a
chi-square test. To understand the relationship between
outcome and the predictors of interest, both the Cox-
TVC and Gray’s models were fit to the data. All-cause
and cause-specific mortality analyses for cardiovascular,
cardiac, and infectious diseases included the following
variables in addition to the diabetes variables: age, race,
BMI, years of dialysis, Kt/V, flux, dialysis access, ICED,
systolic and diastolic blood pressure, smoking, calcium,
phosphorus, and serum albumin.
Cox’s time dependent covariate model. The Cox pro-
portional hazards model depends on the assumption of
a constant hazard over time. That means the hazard in
the diabetic group is a constant proportion of the hazard
in the non-diabetic group. If a time varying covariate is
used in a Cox model then proportional hazard assump-
tion violates. While this assumption holds in many dif-
ferent applications, the model can provide misleading
results when the hazard function changes over time. To
accommodate this possibility, the standard Cox propor-
tional hazards regression model can be extended to fit a
model with time varying covariates [7,9]. In Cox-TVC
model the values of the covariate may vary over time.
For example, diabetic status of an individual may vary
over time whereas race is constant over time. We fit sin-
gle predictor Cox-PH models for each of the variables
considered for analysis and tested the proportional
hazards assumption. For diabetes, a variable that does
not satisfy the proportional hazards assumption, we cre-
ated a time-varying covariate that included diabetes sta-
tus by time. We assessed the influence of including
other covariate by time interactions in the model and
found that there was very little influence in the inter-
pretation of the risk associated with diabetes. Therefore,
the more parsimonious model using the diabetes status
by time covariate was examined. The final multivariable
Cox-TVC model was fit using a significance level of 0.15
as a cutoff for inclusion in the model, with the exceptionof the variables for study interventions and diastolic
blood pressure.
Gray’s time varying coefficient model. The use of time
varying covariate in the Cox model involves the choice
of complex functional form of the covariate and requires
deep biologic insight. It also may lead to potential bias,
and does not lead to prediction for the individual sur-
vival experience as does the usual Cox model with fixed
covariate values [13]. The statistical formulation of
Gray’s model is very similar to the Cox proportional
hazards model with the hazard function being a more
general version of the function used to fit Cox’s model.
For Gray’s model, the regression coefficients differ across
set time intervals allowing for the inclusion of non-
proportional hazards and providing a better description
of the change in risk over time. During each time
interval, the rise is assumed to be constant; i.e., the
proportionality of hazards is assumed to hold within
but not between successive intervals. Assuming that
the recorded survival times divided into c + 1 time inter-
vals 0; t1 Þ; t1; t2 Þ;⋯; tc1; tcð Þ; tcð Þ;ðð where the last
interval includes the largest observed time. Then the
hazard function for the Gray’s model is given by
hðt;xÞ ¼ h0 tð Þ expðxβkÞ , k ¼ 1;⋯; cþ1 , for t lies be-
tween tk1 and tk . Based on Gray’s model, there will be
cþ1ð Þ βs associated with each covariate. Gray’s model
relies on a flexible spline model to include these changes
over time, requiring the specification of the number of
time intervals needed to fit the model. The model out-
put then includes a regression coefficient for each of the
time intervals, a test of the overall statistical significance
of the regression coefficients, and a test of proportional-
ity through a test of the equality of the coefficients over
time. The models presented here have been fit using 10
time intervals, so that each interval contains approxi-
mately the same number of mortality events [8]. We
examined both single predictor Gray’s models as well as
models that included multiple predictors. As with the
Cox regression models, we used a significance level of
0.15 as inclusion criteria for any variables considered for
modeling. The statistical formulation and technical
details for Gray’s model can be found in [8,9]. We used
Stata 10 and R software for fitting the Cox-TVC model
and Gray’s model respectively.Results
Baseline characteristics of the HEMO study participants
are shown in Table 1. In the HEMO Study, 823 (44.6%)
participants were classified as diabetic. Diabetic patients
were more likely to be older, female, and have a higher
BMI, and were more likely to have tunneled dialysis
catheters compared to non-diabetic participants. Dia-
betics had a higher burden of comorbid disease (higher
Table 1 Baseline Characteristics of 1846 HEMO Dialysis Patients, USA, 1995-2000
Factors All Patients (N = 1846) Diabetic (N = 823) Non-Diabetic (N = 1023) P-valuea
Age 57.62(14.04) 61.19(11.38) 54.75(15.27) <0.01
Female sex (%) 56.23 63.67 50.24 <0.01
Black race (%) 62.62 64.76 60.90 0.09
BMI 25.46(5.28) 26.86(5.35) 24.35(4.95) <0.01
Years of dialysis‡ 2.16[0.94, 4.68] 1.67[0.81, 3.26] 2.83[1.12, 6.46] <0.01
Residual urine output (%)† 12.02 12.94 11.29 0.29
High Kt/V (%) 49.84 49.70 49.95 0.91
High flux (%) 49.89 50.06 49.76 0.90
Access
Permanent Catheter (%) 5.80 6.80 4.99 <0.01
AVF/AVG/Other (%) 94.20 93.20 95.01
Co-morbidity ICED score (%)
0-1 35.59 22.84 45.85
2 31.26 33.41 29.52 <0.01
3 33.15 43.74 24.63
Blood pressure
Systolic 151.02(25.64) 155.92(25.87) 147.08(24.78) <0.01
Diastolic 81.28(15.24) 79.93(15.01) 82.36(15.35) <0.01
Smoking (%)
Never 50.24 54.20 47.06 <0.01
Past 32.39 34.10 31.02
Current 17.36 11.69 21.92
Calcium (mg/dL) 9.34(0.99) 9.27(0.93) 9.40(1.04) <0.01
Phosphorus (mg/dL) 5.85(1.83) 5.71(1.76) 5.96(1.89) 0.01
Serum Total Cholesterol(mg/dl) 171.39(40.01) 170.20( 40.48) 172.35(39.62) 0.26
Serum albumin(g/dl) 3.63(0.36) 3.55(0.33) 3.68(0.37) <0.01
Abbreviations: BMI, body mass index; AVF, arteriovenous fistula; AVG, Arteriovenous grafts; ICED, Index of Coexistent Disease.
a All P values are two-sided.
†If the patient produces ≥200 ml/day of urine, is urea clearance measured from interdialytic urine collection >1.5 ml/min (per 35 L of total urea volume). (0 = no,
either produces <200 ml/day or urea clearance ≤ 1.5 ml/min, 1 = yes, 9 = unknown, to be determined during Baseline).
‡ Continuous and skewed variables are summarized in the form of Median [1st Quartile, 3rd Quartile].
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pressure. On the other hand, diabetic patients were less
likely to be current smokers and had lower phosphorus.
Albumin was significantly lower in the diabetic group
compared to non-diabetics. We examined the stability
of diabetes classifications over time. In year 1, 17 of
the 761 classified as non-diabetic alive at year 1 were
reclassified as diabetic. There were no diabetics reclas-
sified as non-diabetics. Hence, 17 of 1316 alive at year
1 were reclassified overall. The diabetes classification
remained stable during the rest of the HEMO study
period when we examined changes from baseline to
years 2–6.
The crude hazard estimates obtained from the Cox-
PH model and Gray’s model are shown in Table 2. First,
unadjusted analyses of all covariates were performed and
the proportionality assumption was tested using theSchoenfeld residuals. The residual tests indicate that
most of the covariates satisfy the proportional hazards
assumption with the exception of diabetes (p = 0.05),
duration of dialysis (p = 0.05), systolic blood pressure
(p <0.01), smoking (p = 0.03), and albumin (p <0.01).
Note, residual urine output violates the PH assumption
(p = 0.05) but it was not considered in the multivariable
adjusted models since its significance levels are higher
than the cutoff point after using residual urine output
and time as an interaction term. While the Cox hazard
estimate is presented with a p-value derived from the
Wald score, the output from Gray’s model provides the
range of the hazard ratios across time and the statistical
test results from the global test [8] of a nonzero hazard
rate. Using the Cox-PH model, the presence of diabetes
was associated with a higher risk of death with the HR
equal to 1.64; while the HR ranged from 1.46 to 2.21 in
Table 2 Baseline Risk Factors and Associated Mortality Using Unadjusted Cox Proportional Hazard (Cox-PH) and Gray’s
Survival Models
Variables Cox-PH Model PH test Grays Model
H.R.a
Estimate [LL, UL]
P-value P-value H.R. Rangeb
(min – max)
P-value
Diabetes 1.64 [1.43, 1.87] <0.01 0.05 1.46-2.21 <0.01
Age£ 1.46 [1.38, 1.55] <0.01 0.98 1.44-1.50 <0.01
Female sex 1.01 [0.88, 1.16] 0.88 0.13 0.91-1.19 0.52
Black race 0.73 [0.64, 0.84] <0.01 0.09 0.68-0.93 <0.01
BMI 0.98 [0.97, 0.99] <0.01 0.28 0.96-0.99 <0.01
Yrs of Dialysis 0.99 [0.97, 1.00] 0.18 0.05 0.99-1.01 0.08
Residual urine output 0.97 [0.77, 1.22] 0.80 0.05 0.73-1.22 0.23
≥200 ml/day urine
High Kt/V 0.95 [0.83, 1.08] 0.41 0.72 0.91-0.96 0.88
High Flux 0.95 [0.83, 1.08] 0.41 0.15 0.87-1.11 0.33
Access(Cather vs. All other) 1.91 [1.47, 2.47] <0.01 0.79 1.75-2.02 <0.01
Comorbidity ICED Score 1.57 [1.44, 1.70] <0.01 0.79 1.51-1.67 <0.01
Blood Pressure
Systolic* 0.97 [0.91, 1.04] 0.37 <0.01 0.99-1.00 0.01
Diastolic* 0.80 [0.75, 0.86] <0.01 0.38 0.80-0.87 <0.01
Smoking(Smoked vs. Never) 1.08 [0.99, 1.18] 0.09 0.03 0.95-1.18 0.04
Calcium (mg/dL) 0.93 [0.86, 0.99] 0.03 0.08 0.85-1.01 <0.01
Phosphorus (mg/dL)* 0.98 [0.91, 1.05] 0.55 0.49 0.95-1.01 0.87
Total Cholesterol (mg/dL)* 0.99 [0.92, 1.06] 0.78 0.95 0.97-1.02 0.95
Albumin (mg/dL) 0.57 [0.52, 0.63] <0.01 <0.01 0.44-0.66 <0.01
Abbreviations: BMI, body mass index; ICED, Index of Coexistent Disease; PH, proportional hazard, H.R., hazard ratio.
a Hazard Ratio (HR) estimate for each risk factor is presented in the second column which is obtained by fitting the Cox’s time varying single covariate model.
b A range of HR estimates are obtained for each covariate by fitting Gray’s model. £ Age has been rescaled by dividing 10 for better interpretation of the HR.
*Blood pressure, phosphorus, and total cholesterol have been rescaled by dividing standard deviation for better interpretation of the HR.
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associated with the covariates was similar across the two
methods with the exception of smoking and systolic
blood pressure which were not significant in the Cox-
PH model, but had a significant effect when using Gray’s
model. Years of dialysis was non-significant in the Cox-
PH model but approached significance in Gray’s model
(p = 0.08). The HR estimates from the Gray’s models for
all time intervals can be found in the supplementary
table, “Additional file 1: Table S2”.
The adjusted hazards for all-cause mortality from both
the Cox and Gray’s survival models are presented in
Table 3. After fitting the multivariable standard Cox-PH
model for all causes mortality survival data, the Schoen-
feld residuals test indicated that the model violated the
proportional hazard assumption (global test, p <0.01;
diabetes, p = 0.07). In the Cox model with time-varying
covariates the hazard ratio (HR) for diabetes is 1.57,
p = 0.11, and the interaction between diabetes and time
has a HR of 1.13 with p = 0.02. The combined test for
diabetes and diabetes × time using the likelihood ratio
test was significant with a chi-square = 7.04 and p = 0.03.At the 1st and 6th year the hazard ratios are 1.77 and
3.22 respectively. When systolic blood pressure was
included in the model using an interaction term with
time, there was no substantial change in the hazard for
diabetes. Using Gray’s model the HR for diabetes ranges
from 1.41 to 2.21 with p <0.01. In the multi-predictor
models of all-cause mortality, the estimates for other
covariates were similar for most of the covariates. The
corresponding p-values for the variables BMI, years of
dialysis, smoking, and phosphorus are very similar for
these two models (Table 3). There were some slight dif-
ferences in the interpretation of the coefficients between
the two models. For example, systolic blood pressure
was associated with a HR of 0.98 using the Cox model
and the estimate of the HR with Gray’s model ranged
from 0.88-1.07. For serum calcium which was not statis-
tically significant (at 5% level) using Cox’s model with
time-varying covariates, the results obtained from Gray’s
model indicated that the relationship was significant
with the HR ranging from 0.87-1.00. The HR estimates
from the Gray’s model for all time intervals can be found
in the supplementary table, “Additional file 2: Table S3”.
Table 3 Multi-Predictor Cox and Gray’s Survival Models for HEMO Dialysis Patients’ Population
Variables Cox-TVC Model Grays Model
H.R. P-value H.R. Range
(min-max)
P-value
Diabetes 1.57 [0.91, 2.73] 0.11 1.41-2.21 <0.01
Diabetes × time 1.13 [1.02, 1.25] 0.02 – –
Age 1.44 [1.34, 1.55] 0.00 1.41-1.48 <0.01
Female Sex 1.08 [0.87, 1.34] 0.51 0.99-1.23 0.86
Diabetes × Sex 0.75 [0.55, 1.01] 0.06 0.59-0.85 0.05
Black Race 0.72 [0.62, 0.84] <0.01 0.65-0.83 <0.01
BMI 0.97 [0.95, 0.98] <0.01 0.95-0.99 <0.01
Yrs of Dialysis 1.03 [1.01, 1.04] 0.01 1.01-1.04 0.01
High Kt/V 0.97 [0.83, 1.12] 0.64 0.89-1.04 0.84
High Flux 0.94 [0.81, 1.09] 0.43 0.83-1.23 0.11
Access(Catheter vs. All other) 1.67 [1.24, 2.24] <0.01 1.41-2.00 <0.01
Comorbidity ICED Score 1.39 [1.26, 1.53] <0.01 1.23-1.55 <0.01
Blood Pressure
Systolic 0.98 [0.89, 1.09] 0.74 0.88-1.07 0.07
Diastolic 0.92 [0.83, 1.02] 0.12 0.89-0.95 0.30
Smoking (Smoked vs. Never) 1.15 [1.03, 1.27] 0.01 1.03-1.24 0.01
Calcium(mg/dL) 0.93 [0.87, 1.00] 0.07 0.87-1.00 0.04
Phosphorus(mg/dL) 1.12 [1.03, 1.21] 0.01 1.09-1.15 0.02
Albumin(mg/dL) 0.70 [0.62, 0.78] <0.01 0.61-0.77 <0.01
Abbreviations: BMI, body mass index; AVF, arteriovenous fistula; AVG, Arteriovenous grafts; ICED, Index of Coexistent Disease, H.R., hazard ratio.
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for all-cause and cause- specific mortality for diabetes as
estimated from each of the three models; the Cox-PH
model(dash line), the Cox model with time-varying cov-
ariates(light solid line) and Gray’s model(solid line in-
cluding 95% confidence interval). While diabetes violates
the PH assumption for all-cause mortality, it does not
violate the PH assumption for the three cause-specific
mortalities (Schoenfeld residuals test, p >0.05). For bet-
ter comparison, we have plotted the hazard ratios from
the Cox-PH model which is basically a straight line
intercepting with y-axis at different levels depending on
the types of mortality considered. For the Cox model
with time-varying covariates, the plot includes the haz-
ard ratio associated with both the diabetes and dia-
betes × time interaction terms. For Gray’s model the
confidence interval associated with each hazard ratio is
also provided. For all-cause mortality (panel a), the Cox-
TVC model provides an estimate of risk below that of
the Gray’s method. Both the Cox-TVC and Gray’s
method demonstrated a higher long-term risk associated
with diabetes than the adjusted Cox proportional
hazards model. For cardiac mortality (panel b), the Cox
proportional hazard ratio estimate for diabetes was 1.81,
95% CI [0.79, 4.15] (Schoenfeld residuals test, p = 0.30).
Again, there was not a significant interaction with time(p = 0.07) for the Cox-TVC, and Gray’s method provided
a very similar estimate of risk for the first four years in
the study and the risk increased in years 5 and 6. For
cardiovascular mortality(panel c), the Cox-TVC model
provides an estimate of risk below that of Gray’s method
for the first two years, then Gray’s method and the Cox-
TVC are approximately similar through five years. Both
the Cox-TVC and the Gray’s method demonstrated a
higher long-term risk associated with diabetes than the
adjusted Cox proportional hazards model. For infectious
mortality (panel d), the hazards estimated for diabetes
from the three methods appear similar for the first
4 years then estimates differ depending on the methods
used.
Discussion
This work demonstrated that diabetes was associated
with an increasing risk of cardiac, cardiovascular and all-
cause mortality over time in the HEMO study. There
was no increase in risk from infectious mortality asso-
ciated with diabetes. The use of the HEMO study to as-
sess the risk of death in the hemodialysis population
takes advantage of a randomized, controlled dialysis trial
with stratification using diabetes and provides the op-
portunity to account for the level of comorbidity using
the ICED. This ability to adjust for differences was
Figure 1 All-cause and Cause-specific Adjusted Hazard Ratio for Diabetes Over Time in HEMO Study Patients§§. §§ (a) All-cause
mortality HR estimate using the Cox’s proportional hazards (Cox-PH) is 2.11 (p = 0.003), HR for DM using Cox-TVC model is 1.57 (p = 0.11) for
main effects and 1.13 (p = 0.02) for the interaction term, Gray’s model estimates are 1.41 to 2.21 (p <0.001). (b) Cardiac mortality HR estimate
using the Cox-PH is 1.81 (p = 0.16), HR for DM using Cox-TVC model is 1.22 (p = 0.68) for main effects and 1.18 (p = 0.07) for the interaction term,
Gray’s model estimates are 1.70 to 2.46 (p = 0.003). (c) Cardiovascular mortality HR estimate using the Cox-PH is 2.00 (p = 0.06), HR for DM using
Cox-TVC model is 1.28 (p = 0.55) for main effects and 1.21 (p = 0.02) for the interaction term, Gray’s model estimates are 1.58 to 2.46 (p = 0.001).
(d) Infectious mortality HR estimate using the Cox-PH is 2.01 (p = 0.22), HR for DM using Cox-TVC model is 1.48 (p = 0.53) for main effects and
1.12 (p = 0.27) for the interaction term, Gray’s model estimates are 1.17 to 2.21 (p = 0.21).
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distribution of characteristics by diabetes in HEMO.
These findings demonstrate that the risk of death asso-
ciated with diabetes in ESRD increases over time and
suggest that an increasing risk of death among diabetes
may be underappreciated when using conventional sur-
vival models.
These findings extend earlier work demonstrating an
increased risk of death from diabetes among both
hemodialysis patients and within the general population
[14,15]. While ESRD confers an increased risk of mortal-
ity [16], previous research has shown that the risk of
death is even higher among ESRD patients with diabetes
when compared to non-diabetic ESRD patients, indicat-
ing that diabetes confers an independent mortality risk
[17-19]. Villar et al. analyzed the data from the ANZ
Dialysis and Transplant Registry and assessed the risk
factors for death using Cox regression demonstrating
that the adjusted hazard ratio of death was 1.64 in type
1 diabetics and 1.13 in type 2 diabetics compared to
non-diabetic patients with ESRD [3]. Van DijK et al. ana-
lyzed the data from 10 registries in Europe and found
the diabetes was associated with an increased risk ofdeath in ESRD population [2]. A comparison of out-
comes between diabetic and non-diabetic CAPD patients
was performed by Prasad et al.; this study showed that
diabetes was associated with an odds ratio of 1.95 (CI
1.23-3.07) for overall mortality [20]. Survival of patients
on maintenance hemodialysis over a twenty year period
was analyzed by Sikole et al. who showed that
hemodialysis patients with diabetes had a lower survival
rate compared to patients with glomerulonephritis and
adult polycystic kidney disease [21]. Since the Membrane
Permeability Outcome (MPO) study demonstrated that
diabetic patients in the high flux arm had better survival
probability than the diabetic patients in the low flux arm
[22], it is important that these findings from the HEMO
study accounted for assignment to the high flux arm.
The increased risk of death associated with diabetes in
the HEMO study was due to cardiac and cardiovascular
mortality rather than infectious mortality.
These findings from the HEMO study demonstrate an
increasing risk of mortality over time associated with
diabetes in prevalent hemodialysis patients which may
relate to the accumulation of end-organ damage or med-
iators of inflammation and oxidative stress. The
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the course of many years can theoretically be responsible
for an increasing risk of all-cause and cardiovascular
mortality due to diabetes over time. The pathophysio-
logical basis of structural and functional changes due to
diabetes which may lead to endothelial dysfunction and
increased cardiovascular risk is thought to involve oxida-
tive stress and production of advanced glycosylated pro-
ducts [23-25]. Previous research studying the effect of
diabetes on mortality in ESRD patients have assumed
that the risk of mortality (or hazard ratio) due to dia-
betes remains constant over time and have utilized the
Cox proportional hazards model to estimate the effects
of diabetes. However, diabetes may violate the propor-
tionality assumption required by the Cox model, leading
to an inaccurate estimate of risk. In this situation alter-
native approaches, such as Cox models that include time
interactions (TVC) or Gray’s [8] extension of the Cox
model may be used to better estimate the risk associated
with diabetes. Gray’s modeling technique has been
applied to many other areas of biomedical research
with the reporting of survival probabilities [9]. In sum,
this work suggests that using the standard survival
model underestimates the burden of diabetes among
hemodialysis patients in the HEMO study.
These findings should be interpreted in light of several
limitations. Gray’s model requires estimation of a large
number of coefficients (default is 10) for a variable in
the model and hence it requires larger sample sizes [9].
This limitation was overcome by our selection of the
HEMO Study, which is a large trial of hemodialysis
patients. In our comparison of two models: Cox-TVC
and Gray’s model, we do not have a ‘gold standard’
model for comparison. Also, the HEMO study studied
prevalent hemodialysis patients rather than incident
patients which could create a survivorship bias.
However, the mortality rates in HEMO were similar to
those seen in the USRDS cohort [6]. Also, the use of
prevalent patients addresses an important subgroup of
hemodialysis patients since while the adjusted mortality
rates have declined over the past two-decades for
patients exposed to less than 5-years of dialysis, those
patients with greater than 5-years of dialysis exposure
have not experienced these gains in survival [26]. Fur-
thermore, the available source of data did not allow us
to make an accurate distinction between Type 1 and
Type 2 diabetes, so that potential differences between
diabetes subtypes are not accounted for in this analysis.
Conclusions
Our findings of increasing risk of all-cause mortality and
cardiovascular and cardiac mortality demonstrate that
the burden of diabetes increases over time among
hemodialysis patients. This finding is important forunderstanding the burden of diabetes among patients
with ESRD and may contribute to our interpretation of
the pathophysiology of diabetes. This work also builds
on reviews of time-to-event analysis in ESRD by apply-
ing flexible survival approaches to better understand
outcomes among the ESRD population [27]. These
approaches provide more precise estimates for the out-
comes of diabetics undergoing hemodialysis. Using this
information may permit the patient to weigh the deci-
sion to start dialysis or to consider evaluation for kidney
transplantation. Further studies could combine novel
methods for survival analysis with longitudinal assess-
ment of biomarkers such as C- reactive protein or mar-
kers of oxidative stress to better understand the strong
association of diabetes with an increasing risk of death
in prevalent hemodialysis patients.Additional files
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